TMO
$693.02+1.19%
as of close, Oct 27, 2026
☾ AH $693.02 +1.19%
Thermo Fisher Scientific Inc.Stock · HealthcareS&P 500 · 0.3% of SPYRussell 1000 · 0.3% of IWBUS Stock Market · 0.3% of VTIRussell 3000 · 0.3% of IWVMSCI World · 0.2% of URTHS&P 500 Equal Weight · 0.2% of RSPMSCI ACWI · 0.2% of ACWI
TMO — Thermo Fisher Scientific Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeDDDDDDDDDDDDDDDDDDDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDE
150.0200.0250.0300.0350.0400.0450.0500.0550.0600.0650.0010.0M20.0M$693.02—20162019202120242026
2026-10-27
Price$693.02
MA20$577.39
MA50$551.49
Vol9.4M
Key stats#
Price data
- Price
- $693.02
- YTD price return
- +19.60%
- YTD total return
- +19.93%
- Market cap
- 256.2B
- Enterprise value
- 296.5B
- Shares outstanding
- 369.7M
- 52W low
- $435.27
- 52W high
- $705.79
- From 52W high
- -1.81%
- From 52W low
- +59.22%
- 52W range
- 95%
- Beta
- 0.85
Volume
- Rel volume
- 0.73×
- 30D volume
- 2.5M
- 30D $ vol
- 1.7B
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- −$61.3M
- Insider net 1Y
- −$69.9M
Form 4 transactions by trade date, as filed; latest on file 2026-08-31.
Fundamentals
- Sales (ttm)
- 46.3B
- Sales/share
- $125.32
- EPS (ttm)
- $18.58
- FCF (ttm)
- 7.3B
- FCF/share
- $19.79
- Book value/share
- $142.47
- Net margin
- 15.04%
- ROE
- 13.23%
- ROA
- 6.16%
- Debt / equity
- 0.74×
- Current ratio
- 1.55
Growth (CAGR, ttm) · 10Y
- Sales
- +7.26%+2.12%+3.92%+10.18%
- Net income
- +5.84%+6.78%-4.14%+13.33%
- FCF
- +18.68%+7.75%-2.09%+9.77%
- Shares
- -2.09%-1.42%-1.24%-0.64%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +7.54%+8.24%-3.00%+14.07%
- Sales/share
- +9.54%+3.59%+5.23%+10.89%
- FCF/share
- +21.21%+9.31%-0.87%+10.48%
- Book value/share
- +6.53%+7.94%+8.78%+10.22%
- Dividend/share
- +9.79%+11.50%+13.45%+11.63%
- Price
- +22.94%+17.11%+2.51%+16.69%
- Total return
- +23.37%+17.49%+2.80%+17.02%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 37.3×
- P/OI (ttm)
- 31.5×
- Fwd P/E
- 24.3×
- P/S (ttm)
- 5.5×
- P/B (mrq)
- 4.9×
- P/FCF (ttm)
- 35.0×
- EV/EBITDA (fy)
- 29.2×
- EV/Sales (ttm)
- 6.4×
- FCF yield (ttm)
- 2.86%
- Dividend yield (fwd)
- 0.27%
- Dividend yield (ttm)
- 0.27%
- Dividend/share (fwd)
- $1.88
- Buyback yield (realized, 1y)
- 2.09%
- Shareholder yield (realized, 1y)
- 2.52%
- Buyback yield (cash, ttm)
- 1.95%
- Shareholder yield (cash, ttm)
- 2.21%
Vs own 10Y history
- P/E
- 83rd
- P/OI
- 91st
- P/S
- 86th
- P/B
- 71st
- P/FCF
- 86th
Bar = where today’s multiple sits in TMO’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-27#
1D
+1.19%
5D
+0.82%
1M
+2.67%
3M
+23.86%
YTD
+19.60%
1Y
+22.92%
5Y
+13.18%
Recent filings#
- Oct 21Earnings · Earnings release — EPS $6.68 vs $6.40 est. (+4.4%) 1.0%
- Aug 19Insider sale · Britt Lisa P. (Sr. VP and Chief HR Officer) sold 17,290 shares for $10.4M on 2 days since Aug 6
- Aug 7Insider sale · Holmes Joseph R. (VP & Chief Accounting Officer) sold 420 shares for $246K at $584.81
- Jul 23Earnings · Earnings release — EPS $6.03 vs $5.71 est. (+5.6%); revenue $11.99B (+10% y/y) 8.7%
Financial statements
Open full TMO financials →Loading financial statements…
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +8.32% | +0.22% |
| JNJ | Johnson & Johnson | -0.92% | +0.91% |
| ABBV | AbbVie Inc. | +8.34% | -0.12% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +8.98% | -0.08% |
| MRK | Merck & Co. Inc. | -4.68% | +0.86% |
| NVS | Novartis AG | +7.84% | +1.98% |
| AMGN | Amgen Inc. | +8.04% | +0.75% |
| GILD | Gilead Sciences Inc. | +5.40% | +0.25% |
